Online inquiry

IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13272MR)

This product GTTS-WQ13272MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13272MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3610MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ4230MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ5276MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ12668MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ1481MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ12606MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ6192MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ10179MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW